CONFERENCE UPDATE: ACC 2022

Sotagliflozin reduces major adverse CV events: The scored trial

28 Jun 2022


References
  1. Deepak B et al. Sotagliflozin Significantly Reduces Cardiovascular Death, Myocardial Infarction, And Stroke in The Scored Trial. Presented at American College of Cardiology Meeting 2022; April 2-4, 2022.
SGLT2 INHIBITORS
SGLT1 INHIBITORS
SOTAGLIFLOZIN
MAJOR ADVERSE CARDIOVASCULAR EVENTS
DIABETES MELLITUS
CHRONIC KIDNEY DISEASE
HEART FAILURE
CV DEATH
HOSPITALIZATION FOR HEART FAILURE
URGENT HEART FAILURE VISITS
MI
STROKE
Related Articles